We serve Chemical Name:methyl (E)-3-methoxy-2-[2-(6-methoxypyrimidin-4-yl)oxyphenyl]prop-2-enoate CAS:475479-10-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![methyl (E)-3-methoxy-2-[2-(6-methoxypyrimidin-4-yl)oxyphenyl]prop-2-enoate](https://a.dearchem.com/CAS2/475479-10-8.png)
Chemical Name:methyl (E)-3-methoxy-2-[2-(6-methoxypyrimidin-4-yl)oxyphenyl]prop-2-enoate
CAS.NO:475479-10-8
Synonyms:BEN382;Benzeneacetic acid, α-(methoxymethylene)-2-[(6-methoxy-4-pyrimidinyl)oxy]-, methyl ester, (αE)-;Methyl (2E)-3-methoxy-2-{2-[(6-methoxy-4-pyrimidinyl)oxy]phenyl}acrylate;Benzeneacetic acid,|A-(methoxymethylene)-2-[(6-methoxy-4-pyrimidinyl)oxy]-,methyl ester,(|AE);(E)-Methyl 3-methoxy-2-(2-((6-methoxypyrimidin-4-yl)oxy)phenyl)acrylate
Molecular Formula:C16H16N2O5
Molecular Weight:316.309
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:475.4±45.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.556
PSA:79.77000
Exact Mass:316.105927
LogP:2.62
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like BEN382 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(E)-Methyl 3-methoxy-2-(2-((6-methoxypyrimidin-4-yl)oxy)phenyl)acrylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(E)-Methyl 3-methoxy-2-(2-((6-methoxypyrimidin-4-yl)oxy)phenyl)acrylate Use and application,BEN382 technical grade,usp/ep/jp grade.
Related News: “Slower growth in China is no question,” AstraZeneca CEO Pascal Soriot told investors on the call. “We believe we can continue growing [and] maintain our position of leadership, but it’s going to be more difficult moving forward.” 6-Fluoro-3-oxo-2,3-dihydro-1H-indene-1-carboxylic acid manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit furan-2-yl(1,2,4-triazol-1-yl)methanone suppliers As for the expansion itself, Takeda will build a new 15,000-square-foot manufacturing facility at the site and expand an existing 14,000-square-feet of production space. Takeda has been knocking around the Thousand Oaks area since 1996, the Business Times said. 4-allylthiosemicarbazide vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit furan-2-yl(1,2,4-triazol-1-yl)methanone suppliers As for the expansion itself, Takeda will build a new 15,000-square-foot manufacturing facility at the site and expand an existing 14,000-square-feet of production space. Takeda has been knocking around the Thousand Oaks area since 1996, the Business Times said. 4-allylthiosemicarbazide vendor & factory.
